Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Bolt Biotherapeutics Updates on BDC-4182 Phase 1/2 Progress and Q1 2026 Financials

Bolt Biotherapeutics reported its first quarter 2026 financial results and provided a business update, highlighting the ongoing Phase 1/2 study of its lead immune-stimulating antibody conjugate (ISAC), BDC-4182. The company anticipates initial clinical data from this study, which is enrolling patients with gastric and gastroesophageal cancer, in the third quarter of 2026. BDC-4182 targets claudin 18.2 and has shown promising preclinical anti-tumor activity. Financially, Bolt reported a cash balance of $23.9 million as of March 31, 2026, which is projected to fund operations into 2027, including the completion of the dose escalation portion of the BDC-4182 study. The company also mentioned two other ISAC programs targeting CEA and PD-L1 are on hold pending BDC-4182 proof-of-concept.

• Bolt Biotherapeutics' lead candidate, BDC-4182, a next-generation Boltbody™ ISAC targeting claudin 18.2, is currently in an ongoing Phase 1/2 study for patients with gastric and gastroesophageal cancer. The company expects to report initial clinical data from this study in the third quarter of 2026. Preclinical models demonstrated BDC-4182's significant anti-tumor activity, induction of immunological memory, and superior performance compared to cytotoxic ADCs, even in models with low claudin 18.2 expression. The trial employs a step-up dosing strategy to safely achieve higher doses.
• As of March 31, 2026, Bolt Biotherapeutics reported cash, cash equivalents, and marketable securities totaling $23.9 million. This financial position is anticipated to fund the company's operations into 2027, ensuring the completion of key milestones, including the dose escalation portion of the ongoing BDC-4182 Phase 1/2 study. The company also reported a reduced net loss of $7.2 million for Q1 2026, compared to $11.0 million in Q1 2025, reflecting decreased R&D and G&A expenses due to restructuring.
• Bolt Biotherapeutics has two additional Boltbody™ ISAC programs targeting CEA and PD-L1, which are currently on hold. Development of these programs is planned to resume once BDC-4182 demonstrates proof-of-concept for the ISAC approach. The CEA-targeted ISAC utilizes a novel antibody with high affinity to CEACAM5 and a proprietary TLR7/8 agonist, showing complete and durable anti-tumor responses in preclinical models. The PD-L1 ISAC targets both tumor and immune cells, leveraging a unique mechanism distinct from conventional PD-1/PD-L1 blockade for enhanced immune activation.

Unlocking New Frontiers: BDC-4182's Emerging ISAC Mechanism

The emerging mechanisms of action for gastric cancer over the past three years reveal a rapidly evolving therapeutic landscape centered on immunotherapy breakthroughs and precision targeting approaches. Immunotherapy has established itself as a cornerstone through PD-1/PD-L1 checkpoint inhibition, with pembrolizumab and nivolumab now approved for first-line treatment of PD-L1-positive tumors. The field has advanced beyond single-agent approaches, with combination strategies showing particular promise—immunotherapy combined with chemotherapy in PD-L1-positive cases and dual targeting with trastuzumab plus immunotherapy in HER2-positive/PD-L1-positive tumors. Microsatellite instability (MSI) and deficient mismatch repair (dMMR) have emerged as critical predictive biomarkers, with immunotherapy recommended as first-line treatment for advanced MSI tumors. Additionally, novel immune mechanisms including CTLA-4 pathway blockade and tumor-associated macrophage (TAM) modulation are reshaping the immunotherapeutic approach.

Novel targeted therapy mechanisms have expanded significantly, particularly in HER2-positive disease where antibody-drug conjugate trastuzumab-deruxtecan offers new second-line options after trastuzumab failure, and bispecific antibody zanidatamab shows promise in first-line treatment. Claudin 18.2 targeting with zolbetuximab represents a major advancement for first-line treatment in Claudin 18.2-positive cancers, with approval anticipated in 2024. FGFR2b targeting and VEGFR2 inhibition with ramucirumab continue to demonstrate therapeutic value, while emerging targets include MUC3A antigen for immunotherapy applications and EphA2 receptor for precision drug delivery systems.

The most innovative emerging mechanisms focus on cellular death pathways and tumor microenvironment modulation. Pyroptosis, a proinflammatory programmed cell death pathway, has gained attention for its dual role in both tumor formation and suppression, with pyroptosis-based agents showing ability to inhibit gastric cancer through NLRP3 inflammasome regulation. The cGAS-STING pathway has emerged as a pivotal innate immune mechanism that transforms immunosuppressive tumor environments into immune-stimulating milieus. Novel drug delivery approaches utilizing cancer cell membrane-derived nanoparticles and targeting of RNA m6A methyltransferases like METTL3 represent cutting-edge precision medicine strategies, while nitrogen-containing heterocycle molecules offer new chemotherapeutic mechanisms with improved biocompatibility and reduced toxicity profiles.

BDC-4182 Phase 1/2: Design and Anticipated Milestones

BDC-4182 clinical development in gastric cancer encompasses multiple recent trials with varying designs targeting different patient populations and biomarker-defined subgroups. The most significant studies include antibody-drug conjugate evaluations, biomarker-driven stratification studies, and combination therapy assessments with established standards of care.

Addressing Critical Unmet Needs in Gastric Cancer Treatment

Recent gastric cancer research has intensified focus on several critical therapeutic gaps that continue to challenge clinical outcomes. The heterogeneous nature of gastric cancer, combined with frequent late-stage diagnoses and limited treatment durability, has driven targeted investigations into specific patient populations and resistance mechanisms.

• HER2-targeted therapy resistance represents the most prominent unmet need, with patients developing resistance to trastuzumab despite initial response, particularly affecting HER2-positive, PD-L1 negative metastatic gastric cancer populations who face limited second-line options

• Late-stage detection burden continues as approximately two-thirds of patients are diagnosed at advanced or metastatic stages due to the asymptomatic nature of early disease, resulting in poor treatment outcomes and limited survival benefits from conventional therapies

• Biomarker heterogeneity challenges include spatial and temporal variability in biomarker expression, interobserver variability in assessment, overlapping biomarker positivity complicating treatment selection, and insufficient tissue samples for comprehensive molecular profiling

• Immunotherapy resistance mechanisms limit the efficacy of PD-1/PD-L1 inhibitors, with adverse reactions and acquired resistance hindering broader clinical application despite approvals for pembrolizumab and nivolumab in PD-L1 positive tumors

• Novel target validation needs focus on emerging biomarkers including CLDN18.2-positive disease (targeted by zolbetuximab with expected 2024 approval), FGFR2b-positive populations, and HER2-low gastric cancer (present in 26% of HER2-non-amplified patients)

• Combination therapy optimization addresses the need for effective multi-modal approaches, with ongoing investigations into immune checkpoint inhibition combined with anti-HER2 therapies, particularly following positive KEYNOTE-811 results in HER2-positive tumors

• Personalized treatment strategies remain underdeveloped due to gastric cancer's molecular heterogeneity encompassing multiple subtypes with distinct biological characteristics, requiring individualized approaches based on comprehensive clinical, pathologic, and molecular typing

Bolt's ISAC Platform: A Pivotal Moment for Immune-Stimulating Conjugates

The pharmaceutical landscape is constantly seeking innovative approaches to cancer treatment, particularly for tumors that remain resistant to existing therapies. Immune-stimulating antibody conjugates (ISACs) represent one such promising frontier, designed to directly engage and activate the immune system within the tumor microenvironment. Research indicates that ISACs, by delivering immunostimulatory agents into immune cells, can significantly enhance anti-tumor activity and improve treatment durability, even in immunologically 'cold' tumors that typically respond poorly to conventional immunotherapies. This mechanism holds the potential to overcome limitations seen with other targeted approaches.

Bolt Biotherapeutics is at a critical juncture with its lead ISAC candidate, BDC-4182, which targets claudin 18.2, a tumor-associated antigen prevalent in gastric and gastroesophageal cancers. The anticipated initial clinical data from its Phase 1/2 study in the third quarter of 2026 is not merely an update on a single drug; it is a pivotal moment for the validation of Bolt's entire ISAC platform. Positive data would provide crucial proof-of-concept, potentially unlocking the development of its other ISAC programs, including those targeting CEA and PD-L1, which are currently on hold. This success could also attract significant partnership interest and bolster the company's financial runway, currently projected only into 2027.

However, the stakes are high. The inherent risks of early-stage clinical development mean that BDC-4182 may not translate its preclinical promise into sufficient clinical efficacy or an acceptable safety profile in patients. Furthermore, the strategic decision to pause other programs creates a significant dependency on BDC-4182's success. A negative or inconclusive readout could severely impact the company's ability to secure future funding and advance its innovative platform. For Bolt, and for the broader field of immune-stimulating therapeutics, Q3 2026 will be a defining period.